Advertisement

Advertisement

Breast Cancer
Immunotherapy

Pembrolizumab Monotherapy for Heavily Pretreated Patients With Metastatic Breast Cancer and High Tumor Mutational Burden

Findings from the ASCO-designed phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket trial, reported in the Journal of Clinical Oncology by Alva et al, indicated that pembrolizumab showed activity in heavily pretreated patients with metastatic breast cancer and high mutational...

Breast Cancer

Alpelisib Plus Fulvestrant in PIK3CA-Mutant, Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer After Disease Progression

As reported in The Lancet Oncology by Hope S. Rugo, MD, and colleagues, findings in one cohort of the phase II BYLieve trial indicated activity of the PI3Kα-selective inhibitor and degrader alpelisib plus fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced ...

Breast Cancer

Long-Term Outcomes With Electron Intraoperative Irradiation vs Whole-Breast Irradiation for Early Breast Cancer

As reported in The Lancet Oncology by Orecchia et al, preplanned long-term follow-up in the Italian single-center phase III ELIOT trial continued to show a higher rate of ipsilateral breast tumor recurrence with electron intraoperative radiotherapy vs postoperative whole-breast irradiation, with no ...

Breast Cancer

PENELOPE-B: Palbociclib for Residual Invasive HR-Positive, HER2-Negative Early Breast Cancer After Neoadjuvant Chemotherapy

As reported in the Journal of Clinical Oncology by Sibylle Loibl, MD, PhD, and colleagues, the phase III PENELOPE-B trial has shown that palbociclib plus endocrine therapy did not improve invasive disease–free survival vs placebo plus endocrine therapy in patients with residual invasive hormone...

Breast Cancer
Survivorship

Overweight Breast Cancer Survivors May Be at Increased Risk of Developing a Secondary Malignancy

Breast cancer survivors who are overweight have a statistically significant increased risk of developing second primary cancers, according to results from a study conducted by Feigelson et al and published in the Journal of the National Cancer Institute. “These findings have important public health ...

Breast Cancer

Addition of Alpelisib to Fulvestrant for PIK3CA-Mutant, HR-Positive, HER2-Negative Advanced Breast Cancer: Patient-Reported Outcomes

In an analysis from the PIK3CA-mutant cohort of the phase III SOLAR-1 trial reported in the Journal of Clinical Oncology, Eva Ciruelos, MD, PhD, and colleagues found that the addition of alpelisib to fulvestrant was not associated with significant worsening of global health status/quality of life...

breast cancer
immunotherapy

Melinda L. Telli, MD, on HER2-Positive Breast Cancer: NCCN Guidelines Update

Melinda L. Telli, MD, of Stanford Cancer Institute, discusses highlights of the new NCCN Clinical Practice Guidelines in Oncology®, including nonanthracycline, taxane-based regimens as preferred treatments for patients with HER2-positive breast cancer; newly approved combination therapies such as tucatinib plus capecitabine plus trastuzumab, margetuximab plus chemotherapy, and neratinib plus capecitabine; and recommendations for third line and beyond.

breast cancer

Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment

Linda T. Vahdat, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses results of a phase II trial designed to test the concept that targeting the tumor microenvironment by depleting copper may prevent metastases, essentially disrupting the infrastructure that contributes to tumor spread.

breast cancer

Dennis J. Slamon, MD, PhD, on Exploiting Cancer Biology in Developing New Treatment Paradigms

Dennis J. Slamon, MD, PhD, of the UCLA David Geffen School of Medicine, reflects on the ways in which breast cancer research pioneered the targeted treatment approach, as understanding of the basic biology of tumors deepened and new pathways were uncovered. He sees a future ripe with possibilities for new molecular targets to further improve outcomes for patients with breast cancer and other types of tumors.

Pancreatic Cancer
Hepatobiliary Cancer
Colorectal Cancer
Breast Cancer
Skin Cancer
Lung Cancer
Prostate Cancer
Issues in Oncology

Estimated Shifts in Cancer Incidence and Death Over Next 2 Decades

In the next 2 decades, rankings of incidence and death across cancer types in the United States will undergo important changes, according to new research published by Lola Rahib, PhD, and colleagues in JAMA Network Open. The study estimates that pancreatic cancer is on course to become the...

Breast Cancer

Liquid Biopsy Plus MRI for Predicting Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer

Cirmena et al discussed whether using a liquid biopsy test to assess plasma cell-free DNA (cfDNA) integrity could improve the accuracy of magnetic resonance imaging (MRI) for predicting the achievement of complete response among patients with locally advanced breast cancer who had received...

breast cancer
immunotherapy

Rita Nanda, MD, on Triple-Negative Breast Cancer: Emerging Therapeutic Strategies

Rita Nanda, MD, of the University of Chicago, discusses the latest data on novel treatment strategies for triple-negative breast cancer, including immune checkpoint, PARP, and ATK inhibitors; antibody-drug conjugates; and targeting the androgen receptor.

Breast Cancer

An Oncologist and His Wife Share a Personal Cancer Story

Gastrointestinal oncologist John Marshall, MD, is well known for his candid observations about cancer treatment and research. In 2006, all the scientific intricacies and sociopolitical dramas of oncology coalesced in Dr. Marshall’s life when his 43-year-old wife, Liza, was diagnosed with breast...

Breast Cancer

Breast Cancer Screening With Clinical Breast Examination in Low- and Middle-Income Countries

Globally, breast cancer surpassed lung cancer as the most common cancer among women, with an estimated 2.3 million cases in 2020.1,2 Approximately 685,000 women will die of breast cancer in 2020 around the world. Approximately 24.5% of all cancers in women are breast cancer, and 15.5% of...

Breast Cancer

Clinical Breast Examination Screening Results in Lower Stage at Breast Cancer Diagnosis and Reduced Breast Cancer Mortality in India

In an Indian study reported in the British Medical Journal, Indraneel Mittra, MD, PhD, of Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, and colleagues at Tata Memorial Centre found that breast cancer screening with clinical breast examination vs active surveillance resulted in...

Breast Cancer

Outcomes With Ribociclib Across Intrinsic Subtypes of HR-Positive, HER2-Negative Breast Cancer

In an analysis of several phase III MONALEESA trials reported in the Journal of Clinical Oncology, Aleix Prat, MD, PhD, and colleagues found consistent progression-free survival benefits with the combination of ribociclib plus endocrine therapy vs placebo plus endocrine therapy across all intrinsic ...

Breast Cancer
Immunotherapy

FDA Grants Regular Approval to Sacituzumab Govitecan-hziy for Pretreated Patients With Triple-Negative Breast Cancer

On April 7, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan-hziy (Trodelvy) for patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them...

Breast Cancer
Immunotherapy

Role of Antibody-Drug Conjugates Across Breast Cancer Subtypes

For the treatment of breast cancer, antibody-drug conjugates are emerging as effective players that could impact all subtypes of this disease, according to Kevin Kalinsky, MD, MS, Director of the Glenn Family Breast Cancer at the Winship Cancer Institute of Emory University, Atlanta. In the...

Breast Cancer
Genomics/Genetics

Germline BRCA1/2 and Other Predisposition Genes in Patients With Metastatic Breast Cancer: Prevalence and Association With Prognosis

In a German prospective registry study reported in the Journal of Clinical Oncology, Peter A. Fasching, MD, and colleagues identified the prevalence of germline mutations in BRCA1/2 and other breast cancer risk genes in patients with metastatic disease and found similar prognosis with presence vs...

Breast Cancer
Symptom Management

Low-Dose Tamoxifen for Reduction of Mammographic Density in Women Undergoing Breast Cancer Screening

In the Swedish phase II KARISMA study reported in the Journal of Clinical Oncology, Eriksson et al found noninferior mammographic density reduction and reduced vasomotor symptoms following tamoxifen therapy at 2.5, 5, and 10 mg vs the standard dose of 20 mg among women undergoing breast cancer...

Breast Cancer
COVID-19

Impact of COVID-19 Pandemic on Delivery of Breast Cancer Care in New York

In a single-institution retrospective study focused on a New York City location reported in JCO Oncology Practice, Satish et al found that more than 40% of patients with breast cancer not infected with COVID-19 had a delay or change in care delivery due to the pandemic. Study Details The study...

Breast Cancer
Immunotherapy

Does Adding Adjuvant Concurrent Trastuzumab to Radiotherapy After Lumpectomy for HER2-Positive DCIS Reduce Ipsilateral Recurrence?

As reported in the Journal of Clinical Oncology by Cobleigh et al, the phase III NRG Oncology/NSABP B-43 trial did not show a significant reduction in ipsilateral breast tumor recurrence with the addition of adjuvant concurrent trastuzumab to radiotherapy in women undergoing lumpectomy for...

Colorectal Cancer
Breast Cancer
Prostate Cancer

Does Consumption of Ultra-Processed Food and Drink Increase Colorectal Cancer Risk?

Consumption of ultra-processed food and drink could increase the risk of developing colorectal cancer. This was the conclusion of a large study published by Romaguera et al in Clinical Nutrition based on questionnaires about food behaviors completed by around 8,000 people in Spain. The study, the...

Breast Cancer
Issues in Oncology

Younger vs Older Women With Breast Cancer: Understanding the Differences

Younger women with breast cancer differ from their older counterparts in ways that should be appreciated by their clinicians, according to Ann H. Partridge, MD, MPH, FASCO, Vice Chair of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. At PER’s...

Breast Cancer

I Want to Live Long and I Want to Live Well

I’m a person who doesn’t like uncertainty. I’m also a worrier. So, when my hand kept going to the same spot on the upper part of my left breast near my chest wall, I couldn’t shake the feeling that something wasn’t quite right, which persisted even after a routine mammography failed to find any...

Breast Cancer
Genomics/Genetics

Breast Cancer Susceptibility Genes: Putting the Pieces Together

With the widespread use of multigene panels for germline genetic testing, understanding the cancer risks associated with pathogenic or likely pathogenic variants (ie, mutations) has become increasingly necessary. To identify which genes are breast cancer susceptibility genes, population studies...

Breast Cancer
Genomics/Genetics

U.S. Population–Based Study of Prevalence of and Risk Associated With Breast Cancer–Predisposition Genes

In a U.S. population–based, case-control study reported in The New England Journal of Medicine, Chunling Hu, MD, PhD, of the Mayo Clinic, Rochester, Minnesota, and colleagues identified the prevalence of and breast cancer risk associated with germline pathogenic variants in established and...

Breast Cancer
Lung Cancer
Global Cancer Care

Female Breast Cancer Surpasses Lung Cancer as the Most Commonly Diagnosed Cancer Worldwide

Cancer ranks as a leading cause of death in every country in the world, and, for the first time, female breast cancer is the most commonly diagnosed cancer, overtaking lung cancer, according to a collaborative report from the American Cancer Society (ACS) and the International Agency for Research...

Breast Cancer

Development of Oral Taxane Tesetaxel to Be Discontinued

Following feedback from the U.S. Food and Drug Administration (FDA) in a pre–new drug application meeting, Odonate Therapeutics has concluded that the clinical data package for tesetaxel, an oral taxane tested in patients with metastatic breast cancer, is unlikely to support FDA approval....

Breast Cancer

Distant Metastasis–Free Survival With Adjuvant vs No Adjuvant Chemotherapy According to Genomic and Clinical Risk in Early Breast Cancer

In an updated analysis of the European phase III MINDACT trial reported in The Lancet Oncology, Martine Piccart, MD, and colleagues found confirmatory evidence of the initial finding of a high rate of distant metastasis–free survival among patients with high–clinical-risk but low–genomic-risk...

Breast Cancer

No Benefit Found for Everolimus Plus Adjuvant Hormone Therapy in High-Risk Early-Stage Breast Cancer

Everolimus plus hormone therapy improves outcomes in the advanced disease setting but apparently not in the adjuvant setting, according to the results of the UNIRAD trial, presented as a part of the European Society for Medical Oncology (ESMO) Virtual Plenary program.1 “In the UNIRAD study, after...

Breast Cancer
COVID-19

Time to Treatment Initiation for Breast Cancer During the COVID-19 Pandemic: Single-Institution Study

In a single-institution study reported in JCO Oncology Practice, Hawrot et al found that there was no increase in time to treatment initiation after histologic diagnosis in patients with newly diagnosed breast cancer during the first wave of the COVID-19 pandemic in 2020. However, they did find...

breast cancer
immunotherapy

William J. Gradishar, MD, on Triple-Negative Breast Cancer: NCCN Guidelines Update

William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the latest recommendations from the National Comprehensive Cancer Network for treating patients with triple-negative breast cancer; data on early-stage and advanced disease; and the role of checkpoint inhibitors, antibody-drug conjugates, and PARP inhibitors.

Breast Cancer

DCIS Biologic Risk Signature May Predict Risk of Recurrence and Radiation Benefit After Breast-Conserving Surgery

Women with ductal carcinoma in situ (DCIS) and elevated decision scores had a significantly higher risk of ipsilateral breast events and a greater relative benefit from radiation therapy compared to women with lower decision scores, according to research presented by Mann et al at the Society of...

Breast Cancer

Improving the Prognostic Accuracy of Residual Cancer Burden After Neoadjuvant Chemotherapy for Breast Cancer

An analysis of 546 patients with breast cancer who received neoadjuvant chemotherapy demonstrated that residual cancer burden is prognostic for overall survival, recurrence-free survival, and distant relapse­–free survival, according to research presented by White et al at the Society of Surgical...

Breast Cancer
Immunotherapy

Pembrolizumab vs Chemotherapy in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-119

As reported in The Lancet Oncology by Eric P. Winer, MD, FASCO, and colleagues, the phase III KEYNOTE-119 trial showed no significant improvement in overall survival with pembrolizumab vs investigator’s choice of chemotherapy in the second- or third-line treatment of metastatic triple-negative...

Breast Cancer

Persistent Use of Low-Value Breast Cancer Surgeries Designated for Deimplementation by Choosing Wisely

In a retrospective cohort study reported in JAMA Surgery, Wang et al found persistent use of low-value breast cancer surgeries designated for deimplementation by the Choosing Wisely program, with a wide interfacility variation in use of these procedures. Study Details The study used National Cancer ...

Breast Cancer
Immunotherapy

Novel HER2-Targeted Therapies Pose Sequencing Challenges

With three new HER2-targeted therapies approved in the past 15 months alone, the treatment landscape for patients with metastatic breast cancer has become increasingly crowded. In the third-line setting and beyond, there are now at least eight HER2-targeted agents approved by the U.S. Food and Drug ...

Breast Cancer

Study Finds Regularly Drinking Sugar-Sweetened Soda May Increase Total and Breast Cancer Mortality

New research published by Koyratty et al in Cancer Epidemiology, Biomarkers & Prevention suggests that patients with breast cancer who drink sugar-sweetened beverages regularly are at increased risk for death from any cause, and from breast cancer in particular. Compared to women who never or...

Breast Cancer
Bladder Cancer
Gastrointestinal Cancer
Hepatobiliary Cancer
Lung Cancer
Immunotherapy

FDA Oncologic Drugs Advisory Committee to Review Status of Six Indications Granted Accelerated Approval

Recently, the U.S. Food and Drug Administration (FDA) announced that the agency will hold a public meeting of the Oncologic Drugs Advisory Committee on April 27 to 29 to discuss six indications granted accelerated approval that have since reported results from confirmatory trials that have not...

Breast Cancer

Older Breast Cancer Survivors May Consider Discontinuing Screening Mammography in the Setting of Limited Life Expectancy

Newly issued mammography screening guidelines for breast cancer survivors aged 75 and older recommend discontinuing routine mammography for those with a life expectancy of less than 5 years and considering discontinuation of routine screening for those with a life expectancy between 5 and 10 years. ...

Breast Cancer

Miami Breast Cancer Conference: Genomic Assays Show Utility in Predicting Pathologic Complete Response Rate in Pre- and Postmenopausal Patients With Breast Cancer

New data from the prospective Neoadjuvant Breast Symphony Trial (NBRST), which demonstrated the predictive and prognostic abilities of the MammaPrint and BluePrint assays and underpinned their preoperative utility in pre-and postmenopausal patients with breast cancer, were presented at PER’s Miami...

Breast Cancer
Immunotherapy

Miami Breast Cancer Conference: Updated DESTINY-Breast01 Results Show Trastuzumab Deruxtecan-nxki Delivers Durable Responses

In updated results from the pivotal DESTINY-Breast01 trial, trastuzumab deruxtecan-nxki (T-DXd) demonstrated high rates of durable responses consistent with prior results, with encouraging progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer. These...

Breast Cancer
Global Cancer Care

New Global Breast Cancer Initiative Highlights Renewed Commitment to Improve Survival

A major new collaborative effort, the Global Breast Cancer Initiative, was introduced by the World Health Organization (WHO), with the objective of reducing global breast cancer mortality by 2.5% per year until 2040, thereby averting an estimated 2.5 million deaths.  In recognition of International ...

Breast Cancer

Outcomes With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer

As reported in The Lancet Oncology by Philip M. Poortmans, PhD, Department of Radiation Oncology of the Iridium Netwerk and the Faculty of Medicine and Health Sciences, University of Antwerp, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reduction in...

Breast Cancer
Genomics/Genetics

Salpingo-Oophorectomy to Reduce Ovarian Cancer Risk in Women With BRCA1 or BRCA2 Pathogenic Variants May Also Reduce Breast Cancer Risk

In a study reported in JAMA Oncology, Choi et al found that risk-reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 pathogenic variants was associated with a reduced risk of breast cancer within 5 years after surgery, with evidence of longer-term risk reduction among those with BRCA1...

Breast Cancer
Global Cancer Care

Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the COVID-19 Pandemic

A new report from Italy published by Toss et al in ESMO Open noted an increase in diagnoses of node-positive and stage III breast cancer after a 2-month interruption in breast cancer screening due to the COVID-19 pandemic. These findings support recommendations for a quick restoration of breast...

Breast Cancer
Issues in Oncology

Adherence to Adjuvant Hormonal Therapy Among Commercially Insured Women With Breast Cancer

In a study reported in JCO Oncology Practice, Zhao et al found that 5-year adherence to adjuvant hormonal therapy was low among commercially insured women with breast cancer in the United States. The retrospective observational study used data from the IBM MarketScan Research Databases to identify...

Breast Cancer

Miami Breast Cancer Conference: Study Examines Response to Neoadjuvant Chemotherapy in Hispanic and Black Patients

Few studies documenting the benefit of neoadjuvant chemotherapy for breast cancer have been conducted in minority populations. A single-institution study reported at PER's Miami Breast Cancer Conference, held virtually this year, confirmed that neoadjuvant chemotherapy improved axillary disease in...

Breast Cancer
Global Cancer Care

Effect of Clinical Breast Examination Screening on Stage at Diagnosis and Breast Cancer Mortality

In an Indian study reported in the British Medical Journal, Mittra et al found that breast cancer screening with clinical breast examination vs active surveillance resulted in younger age and significant downstaging of disease at diagnosis of breast cancer, a significant reduction in breast cancer...

Advertisement

Advertisement

Advertisement